2. Search Result
Search Result
Results for "

systemically

" in MedChemExpress (MCE) Product Catalog:

534

Inhibitors & Agonists

3

Screening Libraries

1

Fluorescent Dye

19

Biochemical Assay Reagents

28

Peptides

1

MCE Kits

37

Inhibitory Antibodies

28

Natural
Products

53

Isotope-Labeled Compounds

4

Click Chemistry

18

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-Y0320C
    Dimethyl sulfoxide
    30+ Cited Publications

    DMSO

    		 Environmental Pollutants Bacterial Cholinesterase (ChE) Inflammation/Immunology
    Dimethyl sulfoxide (DMSO) is an aprotic solvent that can dissolve water-insoluble therapeutic and toxic agents. Dimethyl sulfoxide (DMSO) has a strong affinity for water and has the ability to rapidly penetrate or enhance the penetration of other substances through biological membranes. Dimethyl sulfoxide also has potential free radical scavenging and anticholinesterase effects and may affect coagulation activity. Dimethyl sulfoxide also induces histamine release from mast cells but is thought to have low systemic toxicity .
    Low endotoxin, can be used in various biochemical experiments such as drug dissolution.
    Dimethyl sulfoxide
  • HY-W031727
    Hydroxychloroquine
    85+ Cited Publications

    		 Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy Infection Cancer
    Hydroxychloroquine (HCQ) is a synthetic oral antimalarial drug that can be used in the study of malaria and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is a potent autophagic flux inhibitor with antiviral activity (such as SARS-CoV-2 virus) that inhibits Toll-like receptor 7/9 (TLR7/9) signaling .
    Hydroxychloroquine
  • HY-B0214
    Prednisone
    Maximum Cited Publications
    17 Publications Verification

    Dehydrocortisone

    		 Glucocorticoid Receptor Apoptosis Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus .
    Prednisone
  • HY-111363
    MK8722
    20+ Cited Publications

    		 AMPK Metabolic Disease
    MK8722 is a potent and systemic pan-AMPK activator.
    MK8722
  • HY-P99168
    Anifrolumab
    3 Publications Verification

    MDX-1333; MEDI-546

    		 IFNAR Inflammation/Immunology
    Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .
    Anifrolumab
  • HY-139567
    Afimetoran
    1 Publications Verification

    BMS-986256

    		 Toll-like Receptor (TLR) NF-κB Apoptosis Inflammation/Immunology
    Afimetoran (BMS-986256) is an orally active, selective, and highly bioavailable TLR7/8 antagonist. Afimetoran (BMS-986256) can inhibit TLR7/8 activation of the NF-κB pathway and reverse TLR7 mediated resistance to steroid induced apoptosis in plasma cell like dendritic cells (pDCs). Afimetoran (BMS-986256) can be used for research on inflammation and autoimmune diseases (systemic lupus erythematosus) .
    Afimetoran
  • HY-150095
    YE6144
    2 Publications Verification

    		 IFNAR Inflammation/Immunology
    YE6144 free base is a selective prototypical interferon regulatory factor 5 (IRF5) inhibitor. YE6144 free base suppresses the disease course and is especially effective in remission maintenance in a mouse model of systemic lupus erythematosus (SLE). YE6144 free base can be used for SLE research .
    YE6144
  • HY-B1028
    Pantethine
    5 Publications Verification

    D-Pantethine; LBF disulfide

    		 Endogenous Metabolite SARS-CoV Cardiovascular Disease Neurological Disease Inflammation/Immunology Endocrinology Cancer
    Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .
    Pantethine
  • HY-N7378
    N-Hydroxypipecolic acid
    5 Publications Verification

    1-Hydroxy-2-piperidinecarboxylic acid; NHP

    		 Bacterial Inflammation/Immunology
    N-Hydroxypipecolic acid (1-Hydroxy-2-piperidinecarboxylic acid), a plant metabolite and a systemic acquired resistance (SAR) regulator, orchestrates SAR establishment in concert with the immune signal salicylic acid. N-Hydroxypipecolic acid accumulates systemically in the plant foliage in response to pathogen attack. N-Hydroxypipecolic acid induces SAR to bacterial and oomycete infection .
    N-Hydroxypipecolic acid
  • HY-17402
    Nisoldipine
    2 Publications Verification

    BAY-k 5552

    		 Calcium Channel Reactive Oxygen Species (ROS) Infection Cardiovascular Disease Neurological Disease
    Nisoldipine (BAY-k 5552; Sular) is an orally active and blood-brain barrier-penetrating dihydropyridine calcium antagonist, with greater vascular selectivity than other calcium channel antagonists. Nisoldipine inhibits calcium influx and blocks voltage-gated calcium channels. Nisoldipine dilates coronary and systemic arteries. Nisoldipine has antihypertensive and anti-anginal activity. Nisoldipine also displays neuroprotective and antiviral activity .
    Nisoldipine
  • HY-P990706
    Povetacicept

    ALPN-303

    		 TNF Receptor Inflammation/Immunology
    Povetacicept (ALPN-303) is an engineered Fc fusion protein containing the TACI domain, and acts as a dual APRIL/BAFF antagonist. The Kd value of Povetacicept for human BAFF is 59.3 pM, while its Kd value for human APRIL is 1.00 pM. Povetacicept reduces the activation, proliferation, differentiation and survival of B cells, and inhibits the production of immunoglobulins and autoantibodies. Povetacicept can be used in research related to autoimmune hemolytic anemia, immune thrombocytopenia, systemic lupus erythematosus, lupus nephritis and myasthenia gravis .
    Povetacicept
  • HY-14930
    Mirodenafil

    SK3530

    		 Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis Neurological Disease Inflammation/Immunology Endocrinology
    Mirodenafil (SK3530) is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil is a glucocorticoid receptor (GR) modulator Mirodenafil activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .
    Mirodenafil
  • HY-P99761
    Obexelimab

    XmAb5871

    		 CD19 Apoptosis Inflammation/Immunology
    Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .
    Obexelimab
  • HY-P99842A
    Dapirolizumab

    		Transmembrane Glycoprotein Inflammation/Immunology
    Dapirolizumab is an antibody targeting CD40L (CD154). Dapirolizumab can be used in research related to systemic lupus erythematosus .
    Dapirolizumab
  • HY-P99219
    Sifalimumab

    MEDI-545; MDX 1103

    		 IFNAR Inflammation/Immunology
    Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .
    Sifalimumab
  • HY-14930A
    Mirodenafil dihydrochloride

    SK-3530 dihydrochloride

    		 Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis Neurological Disease Inflammation/Immunology Endocrinology
    Mirodenafil (SK3530) dihydrochloride is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil dihydrochloride is a glucocorticoid receptor (GR) modulator Mirodenafil dihydrochloride activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil dihydrochloride can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .
    Mirodenafil dihydrochloride
  • HY-P990980
    Cizutamig

    CND-106; EMB-06

    		 CD3 Inflammation/Immunology Cancer
    Cizutamig (CND-106) is a bispecific T-cell engager targeting BCMA and CD3. Cizutamig exhibits immunostimulatory and anti-tumor activities. Cizutamig can be used in research related to relapsed or refractory multiple myeloma and systemic lupus erythematosus .
    Cizutamig
  • HY-P99315
    Ruplizumab

    BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8

    		 TNF Receptor Inflammation/Immunology
    Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Ruplizumab
  • HY-P99505
    Ziltivekimab

    COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216

    		 Interleukin Related LDLR Inflammation/Immunology Endocrinology
    Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .
    Ziltivekimab
  • HY-P991267
    CAN10

    		Interleukin Related Inflammation/Immunology
    CAN10 is is a humanized monoclonal antibody inhibitor targeting interleukin 1RAP (IL1RAP). CAN10 blocks IL-1, IL-33, and IL-36 signalling by targeting IL1RAP, preventing downstream proinflammatory and profibrotic responses. CAN10 reduces dermal and pulmonary fibrosis. CAN10 can be used for the research of immune system diseases, such as systemic sclerosis .
    CAN10
  • HY-175739
    TFAM activator 1

    		Mitochondrial Metabolism CXCR Neurological Disease Metabolic Disease Inflammation/Immunology
    TFAM activator 1 is a TFAM activator. TFAM activator 1 increases TFAM protein levels, promotes mitochondrial DNA stability, increases mitochondrial DNA copy number, and prevents mitochondrial DNA from escaping into the cytoplasm. TFAM activator 1 improves cellular energy metabolism in cybrid cells. TFAM activator 1 reduces fibrosis markers in fibroblasts. TFAM activator 1 can be used in the research of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome, systemic sclerosis, and autoimmune diseases .
    TFAM activator 1
  • HY-108882C
    DNase I (filtered)

    		DNA/RNA Synthesis Inflammation/Immunology
    DNase I is an enzyme that degrades DNA. DNase I is mainly produced by digestive system organs, such as the pancreas and parotid gland. Three types of DNase I are known in mammals: pancreatic type, parotid type, and pancreatico-parotid type. DNase I plays a key role in the cleavage of extracellular DNA, and is critical for limiting inflammatory responses and maintaining homeostasis. DNase I is responsible for digesting extracellular nucleoproteins, which may be essential for preventing autoimmune reactions. Decreased DNase I activity may be associated with the occurrence and development of systemic lupus erythematosus (SLE). DNase I (filtered) is filtered through a 0.22 μM membrane and is not tested for pyrogenicity .
    DNase I (filtered)
  • HY-152839
    Elenestinib

    BLU-263

    		 c-Kit Cancer
    Elenestinib (BLU-263) is an orally active inhibitor of Tyrosine kinase with an IC50 value of 6 nM for KIT D816V. Elenestinib minimally penetrates the blood-brain barrier. Elenestinib can be used in the study of systemic mastocytosis .
    Elenestinib
  • HY-150169
    THRX-144644

    		TGF-β Receptor Cancer
    THRX-144644 is a Lung-restricted ALK5 inhibitor with an IC50 value of 0.14 nM. THRX-144644 avoids systemic toxicities associated with TGFβ pathway inhibition .
    THRX-144644
  • HY-15374
    Frentizole

    		Amyloid-β Inflammation/Immunology
    Frentizole, an FDA-approved immunosuppressant, is a Aβ-ABAD (binding alcohol dehydrogenase) interaction inhibitor with an IC50 value of 200 μM. Frentizole is used in studies of diseases related to rheumatoid arthritis and systemic lupus erythematosus .
    Frentizole
  • HY-P3612
    CTCE-0214

    		CXCR Inflammation/Immunology
    CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog. CTCE-0214 shows anti-inflammatory activity, and can be used in inflammation sepsis and systemic inflammatory syndromes research .
    CTCE-0214
  • HY-18620
    DZ2002
    1 Publications Verification

    		 STAT PI3K NF-κB MEK ERK Bacterial Antibiotic Akt Inflammation/Immunology
    DZ2002 is an orally active, reversible and low-cytotoxic type III SAHH inhibitor (Ki=17.9 nM), with good immunosuppressive activity. DZ2002 prevents the development of experimental dermal fibrosis by reversing the profibrotic phenotype of various cell types. DZ2002 can be used in studies of autoimmune diseases such as lupus syndrome and systemic sclerosis .
    DZ2002
  • HY-P99220
    Tabalumab

    LY2127399

    		 TNF Receptor Inflammation/Immunology Cancer
    Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .
    Tabalumab
  • HY-P99358
    Dezamizumab

    GSK 2398852; Anti-Serum Amyloid P/SAP Reference Antibody (dezamizumab)

    		 Complement System Inflammation/Immunology
    Dezamizumab is a fully humanized clonal IgG1 antibody against serum amyloid P component (SAP) with complement activation and amyloid clearance-inducing activities. Dezamizumab binds to SAP associated with amyloid deposits to form complexes that activate complement and mediate phagocytic clearance, triggering activation of the classical complement pathway. Dezamizumab can be used for the research of systemic amyloidosis .
    Dezamizumab
  • HY-B2064
    Carboxin
    4 Publications Verification

    Carboxine; Fenoxan

    		 Environmental Pollutants Antibiotic Fungal Infection
    Carboxin (Carboxine) is a systemic agricultural fungicide and seed protectant.
    Carboxin
  • HY-101795
    Larixyl acetate
    2 Publications Verification

    		 TRP Channel HPV Autophagy Apoptosis PERK Akt Src Infection Cardiovascular Disease Neurological Disease
    Larixyl acetate is a potent and selective TRPC6 inhibitor with IC50 values of 0.58 μM and 6.83 μM against hTRPC6-YFP and hTRPC3-YFP, respectively. Larixyl acetate prevents HPV and is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction .
    Larixyl acetate
  • HY-P99877
    Efavaleukin alfa

    AMG592

    		 Biochemical Assay Reagents Inflammation/Immunology
    Efavaleukin alfa (AMG592) is a IL-2 mutein fragment crystallizable fusion protein. Efavaleukin alfa drives the selective expansion of regulatory T cells. Efavaleukin alfa is applicable to research related to systemic lupus erythematosus .
    Efavaleukin alfa
  • HY-153460
    TLR7/8/9 antagonist 2

    		Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7/8/9 antagonist 2 is an orally active TLR7/8/9 antagonist. TLR7/8/9 antagonist 2 has inhibitory activities for HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC50 values of 0.011 μM, 0.029 μM and 0,052 μM, respectively.TLR7/8/9 antagonist 2 has high bioavailability in vivo.TLR7/8/9 antagonist 2 can be used for the research of auto-inflammatory diseases such as systemic lupus erythematosus or lupus nephritis .
    TLR7/8/9 antagonist 2
  • HY-P990937
    Pacibekitug

    PF-04236921; TOUR-006

    		 Interleukin Related Inflammation/Immunology
    Pacibekitug (PF-04236921; TOUR-006) is a fully humanized IgG2 monoclonal antibody targeting IL-6. Pacibekitug binds to and neutralizes IL-6 signaling, thereby inhibiting the pathophysiological role of this pro-inflammatory cytokine in autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, and systemic lupus erythematosus) [1][2].
    Pacibekitug
  • HY-P99529
    Valziflocept

    BAX1810; TAK-752; SM101

    		 Fc Receptor (FcR) Inflammation/Immunology
    Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE) .
    Valziflocept
  • HY-137978
    Ezurpimtrostat
    3 Publications Verification

    GNS561

    		 SARS-CoV IFNAR Autophagy Apoptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .
    Ezurpimtrostat
  • HY-106690
    Centhaquin

    Centhaquine; PMZ-2010

    		 Adrenergic Receptor Cardiovascular Disease Inflammation/Immunology
    Centhaquine (Centhaquin; PMZ-2010) is a novel agent has the potential for treatment of haemorrhagic shock. Centhaquine (Centhaquin; PMZ-2010) can augment cardiac output, reduce systemic vascular resistance in haemorrhagic models .
    Centhaquin
  • HY-120023
    VU0453595
    2 Publications Verification

    		 mAChR Neurological Disease
    VU0453595 is a highly selective, systemically active M1 positive allosteric modulator (PAM, EC50=2140 nM) for the research of schizophrenia .
    VU0453595
  • HY-P3560
    Edratide

    TV 4710

    		 Apoptosis Inflammation/Immunology
    Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a human anti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis (Apoptosis) and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE) .
    Edratide
  • HY-W062836
    BAY 41-8543

    		Guanylate Cyclase Cardiovascular Disease
    BAY 41-8543 is an orally active, nitric oxide (NO)-independent stimulator of soluble guanylyl cyclase (sGC). BAY 41-8543 has vasodilator activity in the pulmonary and systemic vascular beds in the rat. BAY 41-8543 has antiplatelet effects and has the potential for cardiovascular diseases research .
    BAY 41-8543
  • HY-174270
    NLRP3-IN-79

    		NOD-like Receptor (NLR) Interleukin Related NEKs Inflammation/Immunology
    NLRP3-IN-79 is an orally active NLRP3 inhibitor. NLRP3-IN-79 inhibits NLRP3 inflammasome with an IC50 of 10.69 nM. NLRP3-IN-79 blocks NLRP3 inflammasome assembly by directly binding to NLRP3 and disrupting the NEK7-NLRP3 interaction. NLRP3-IN-79 can be used for the study of NLRP3-driven diseases model, including systemic inflammation, peritonitis, and colitis .
    NLRP3-IN-79
  • HY-P6084
    RP-220

    		NOD-like Receptor (NLR) p38 MAPK Apoptosis Inflammation/Immunology
    RP-220 is a renalase peptide targeting NLRP3. RP220 has anti-inflammatory and anti-apoptotic activities. RP220 inhibits renal tubular epithelial cells apoptosis with alkaline insult by activating MAPK signaling pathway. RP220 significantly inhibits NLRP3 expression and reduces macrophage infiltration and kidney tissue damage in acute kidney injury (AKI) mice model. RP-220 can be uses for systemic lupus erythematosus (SLE) and its complication lupus nephritis (LN) research .
    RP-220
  • HY-B1859
    Isoproturon

    		Environmental Pollutants Herbicide Others
    Isoproturon belongs to the phenylurea herbicide family and is a systemic and selective herbicide. Isoproturon is widely applied for killing weeds in farmland, which can be used in the control of annual grasses and broad-leaved weeds in spring and winter wheat, winter rye and spring and winter barley .
    Isoproturon
  • HY-W031727R
    Hydroxychloroquine (Standard)

    		Reference Standards Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy Infection Cancer
    Hydroxychloroquine (HCQ) is a synthetic oral antimalarial drug that can be used in the study of malaria and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is a potent autophagic flux inhibitor with antiviral activity (such as SARS-CoV-2 virus) that inhibits Toll-like receptor 7/9 (TLR7/9) signaling .
    Hydroxychloroquine (Standard)
  • HY-172374A
    KV1.3-IN-2 hydrochloride

    		Potassium Channel Inflammation/Immunology
    KV1.3-IN-2 hydrochloride is a kv1.3 potassium channel inhibitor without affecting hERG channel activity. KV1.3-IN-2 hydrochloride can be used in research of immune-related diseases such as psoriasis, rheumatoid arthritis, and systemic lupus erythematosus .
    KV1.3-IN-2 hydrochloride
  • HY-B1869
    Metsulfuron-methyl
    2 Publications Verification

    		 Environmental Pollutants Herbicide Others
    Metsulfuron-methyl is a systemic sulfonylurea herbicide that has been widely used to control broadleaf weeds and annual grasses in rice, corn, wheat, and barley. Metsulfuron-methyl exhibits high herbicidal activity and low mammalian toxicity, with an LD50 for rats exceeding 5000 mg/kg .
    Metsulfuron-methyl
  • HY-109143B
    (R)-Elsubrutinib

    (R)-ABBV-105

    		 Btk Inflammation/Immunology Cancer
    (R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor. (R)-Elsubrutinib can be used in studies of immune diseases (such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer .
    (R)-Elsubrutinib
  • HY-172374
    KV1.3-IN-2

    		Potassium Channel Inflammation/Immunology
    KV1.3-IN-2 is a kv1.3 potassium channel inhibitor without affecting hERG channel activity. KV1.3-IN-2 can be used in research of immune-related diseases such as psoriasis, rheumatoid arthritis, and systemic lupus erythematosus .
    KV1.3-IN-2
  • HY-105037A
    Forigerimod TFA

    IPP-201101 TFA

    		 Autophagy Inflammation/Immunology
    Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .
    Forigerimod TFA
  • HY-P2940
    NADase

    		NAMPT Inflammation/Immunology
    NADase is an ectoenzyme/membrane-bound enzyme targeting nicotinamide adenine dinucleotide (NAD +). NADase regulates intracellular NAD + homeostasis by hydrolyzing NAD + into nicotinamide mononucleotide (NMN) and ADP-ribose. NADase is promising for research of autoimmune diseases (e.g., systemic sclerosis, systemic lupus erythematosus) and aging-related disorders .
    NADase

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: